Cell Therapeutics

Source: www.ncbi.nlm.nih.gov --- 39 days ago
Related Articles Cell therapies: realizing the potential of this new dimension to medical Therapeutics. J Tissue Eng Regen Med. 2008 Jul 10; Authors: Singh P, Williams DJ Stem cells promise to treat conditions poorly served by conventional Therapeutics. Cells from both embryonic and somatic tissues are being used to create Cell therapies for genetic, traumatic and degenerative conditions. The current human, healthcare and fiscal costs of these conditions are significant. This review summarizes the use of stem cells for neurological and cardiac disorders and diabetes to determine the requirements for generic translational research to assist such therapies to be a reality. While there are multiple strategies in each disease area, with no clear favourite, there are clear opportunities in treatments that use a single Cell type. A key requirement is to work with pluripotent progenitor cells to cultivate and differentiate a sufficiently large population of functioning cells. Challenges also arise in determining and achieving timely delivery of the correct dose of cells to where they can most effectively treat the disease and best benefit individual patients. Copyright (c) 2008 John Wiley & Sons, Ltd. PMID: 18618613 [PubMed - as supplied by publisher] ...

Source: seattletimes.nwsource.com --- 2 days ago
Cell Therapeutics said Monday that it will need to raise money soon because its current available cash won't last beyond September. ...

Source: blog.seattlepi.nwsource.com --- 8 days ago
Cell Therapeutics said today it would not be able to file its quarterly earnings results on time. ...

Source: seattlepi.nwsource.com --- 2 days ago
Cell Therapeutics executives said Monday that they were closer to spinning off part of the company in a bid to cut costs. ...

Source: blog.seattlepi.nwsource.com --- 27 days ago
Short on cash, Cell Therapeutics said it would sell debt and warrants for $22.5 million to an institutional investor. ...

Source: blog.seattlepi.nwsource.com --- 22 days ago
Cell Therapeutics said in a filing today that it had entered into an agreement with Midsummer Investment Ltd., a Bermuda-based investment company, under which Midsummer can buy 27.8 million shares of Cell Therapeutics' stock (roughly 19.9 percent of the company's outstanding stock). ...

Source: www.prnewswire.com --- 22 days ago
...

Source: www.prnewswire.com --- 3 days ago
...

Source: www.prnewswire.com --- 28 days ago
...

Source: www.marketwire.com --- 23 days ago
CALGARY, ALBERTA (MARKET WIRE) Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE: SSS) announced today that Dr. Allen Davidoff, VP Product Development, will be presenting data from the Phase I open labeled, uncontrolled pharmacokinetic study of a single intra-muscular (IM) hCG dose in healthy male volunteers at the IXth World Conference on Clinical Pharmacology and Therapeutics being held in Quebec City, Quebec, July 27th - August 1st, 2008. ...

Source: www.medicalnewstoday.com --- 22 days ago
Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announced that Dr. Allen Davidoff, VP Product Development, will be presenting data from the Phase I open labeled, uncontrolled pharmacokinetic study of a single intra-muscular (IM) hCG dose in healthy male volunteers at the IXth World Conference on Clinical Pharmacology and Therapeutics being held in Quebec City, Quebec, July 27th - August 1st, 2008. ...

Source: seekingalpha.com --- 2 days ago
Cell Therapeutics, Inc. (CTIC) Q2 2008 Earnings Call Complete Story » ...

Source: www.medicalnewstoday.com --- 43 days ago
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem Cell technologies and Therapeutics, has completed a preclinical study in collaboration with the W.M. Keck Center for Collaborative Neuroscience at Rutgers, The State University of New Jersey. ...

Source: stemcell.taragana.net --- 20 days ago
Stem Cell Therapeutics Corp has today announced that it will present the results of the Phase I open labeled, uncontrolled pharmacokinetic study of a single intra-muscular hCG dose in healthy male volunteers at the IXth World Conference on Clinical Pharmacology and Therapeutics. The Phase I study was conducted to compare blood and cerebrospinal fluid [...] ...

Source: www.earthtimes.org --- 9 days ago
SEATTLE, Aug. 12 -- Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC; MTA) subsidiary Systems Medicine (SM) announced today that planned enrollment is complete in the European Organization for Research and Treatment of Cancer (EORTC) rando... ...

Source: www.seattletimes.com --- 30 days ago
Biotechnology company Cell Therapeutics said Friday in a regulatory filing that without a capital infusion "we will have insufficient funds... ...

Source: www.fiercebiotech.com --- 27 days ago
Seattle-based Cell Therapeutics got a much-needed financial shot in the arm  just days after filing SEC papers that indicated CTI needed new money to continue operations. Cell Therapeutics announced that a single institutional investor--who was not named--has agreed to purchase $44.5 million worth of newly issued 18.33 percent convertible senior notes that are due 2011. The deal comes with a conversion price of $0.79 per share and a warrant to purchase approximately 28.2 million shares of common stock with an exercise price of $0.79 per share. The company says that $22.25 million will be funded this week and the remaining $22.25 million must be funded prior to August 25, 2008. Further funding could be arranged as well. In regulatory filings last week CTI said that "We have an immediate need to raise additional capital in the next thirty days in order to meet our operation needs." And its travails may not be over. In today's announcement CTI stated: "The Company continues to have a substantial amount of debt outstanding and the quarterly interest expense associated with the debt is significant; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses." - read the release Related Articles: Cell Therapeutics running out of cash Cell Therapeutics reorganizes, scales back R&D Cell Therapeutics inks deal to buy cancer drug developer Cell T ...

Source: www.xconomy.com --- 36 days ago
Seattle-based Cell Therapeutics won a victory yesterday in the standoff between Congress and President Bush over a new Medicare bill. Congress voted to overrule Bush’s veto, which would have killed a provision that extended the current reimbursement rate for doctors who prescribe Zevalin, the company’s sole marketed product for non-Hodgkin’s lymphoma. As we wrote about last [...] ...

Source: www.xconomy.com --- 27 days ago
Cell Therapeutics, the Seattle-based developer of cancer drugs, said today it has raised $44.5 million in convertible debt and warrants from a single institutional investor it didn’t name. The notes, which come at 18.3 percent interest and come due in 2011, can convert to stock if Cell Therapeutics’ shares climb above 79 cents. Late Friday, [...] ...